Evaluating Novel Cancer Drugs and Drug Delivery in Preclinical Studies – UROP Spring Symposium 2021

Evaluating Novel Cancer Drugs and Drug Delivery in Preclinical Studies

Emily Fischbach


Pronouns: she, her, hers

Research Mentor(s): Mark Cohen, Assoc. Chair in Surgery, Prof of Surgery, Pharmacology and BME
Research Mentor School/College/Department: Surgery, Michigan Medicine
Presentation Date: Thursday, April 22, 2021
Session: Session 6 (4pm-4:50pm)
Breakout Room: Room 13
Presenter: 1

Event Link


Cancer prevention and treatment in the United States has seen many advances over the last few years, however, breast cancer continues to be one of the most widespread diseases, affecting the lives of approximately one in every eight American women. There is a pressing need for a more effective and less invasive treatment for breast cancer, specifically those cancers that originate in the epithelial cells of the milk ducts or lobules, also known as adenocarcinomas. Heat shock protein 90 (HSP90) has become an important target of many drug treatments. At the molecular level, over-expressed signaling proteins that lead to uncontrollable cell growth are stabilized by HSP90. Recent in vitro studies of the specific HSP90 inhibitors, KU757 and KU758, suggest this drug is effective in treating certain types of cancer, such as thyroid cancer and triple negative breast cancer respectively. This study aims to investigate the efficacy of KU757 and KU758 in treating the breast adenocarcinoma cell line called MCF7. Cell proliferation will be measured by MTS assay, and drug efficacy will be analyzed by calculating inhibitory concentration 50 values.

Authors: Mark Cohen
Research Method: Laboratory Research with Animals

lsa logoum logo